Natalia Galaktionova
About Natalia Galaktionova
Natalia Galaktionova is the Business Head of Oncology & Immunology at Bristol-Myers Squibb in Moscow, with over 20 years of experience in the pharmaceutical industry.
Company
Natalia Galaktionova is currently working at Bristol-Myers Squibb, Princeton, New Jersey, where she serves as the Business Head for Oncology & Immunology based in Moscow. She has held this leadership position since September 2012.
Title
Natalia Galaktionova holds the title of Business Head Oncology & Immunology at Bristol-Myers Squibb. She focuses on managing and advancing the company's business initiatives in oncology and immunology in the Moscow region.
Education and Expertise
Natalia Galaktionova studied Business Administration and Management, General at the Stockholm School of Economics and achieved a Master of Business Administration (MBA) from 2010 to 2012. She also has a background in medical science, having earned a Medical Doctor degree from the Moscow Medical Academy named after I.M. Sechenov, where she studied from 1991 to 1997. Additionally, she pursued Postgraduate education in X-Ray Diagnostics at the National Surgery Center from 1997 to 1999.
Background
Natalia Galaktionova has over 20 years of experience in the pharmaceutical industry. She has worked in various roles including as a Marketing Manager at Bristol-Myers Squibb from 2007 to 2009 and as a Business Unit Head for CNS/IMM from 2009 to 2012. Prior to that, she served as Health Economics and Pricing Manager and as a Product Manager at Janssen Cilag, and as a Product Manager at Pfizer. Her early career includes roles at sanofi-aventis as a Clinical Research Associate and a Medical Representative.
Achievements
Natalia Galaktionova has led the Oncology & Immunology business unit at Bristol-Myers Squibb in Moscow since 2012. Her extensive experience also includes significant roles in clinical research and medical representation, and she has a strong background in health economics, pricing strategies, and product management in the pharmaceutical sector.